New radiopaque/biodegradable drug-eluting beads (DEBs) for transarterial chemoembolization (TACE) were fabricated using Lipiodol and polycaprolactone (PCL) (Lipiodol/PCL beads) through a microfluidic device. TACE is the most extensively-applied therapy for unresectable hepatocellular carcinoma (HCC). DEBs are embolic microspheres with sustained and tumor-selective drug-delivery characteristics for tumor-feeding arteries. As the conventional DEBs are not radiopaque by themselves and not biodegradable, it is difficult to monitor bead localization and attenuation through CT images after DEB-TACE procedures, and the complication after non-target embolization becomes potentially more serious. In this work, we found that our new biodegradable Lipiodol/PCL lost 63.5% of their weight 11 days after immersion, simultaneously releasing 0.94 μg of miriplatin (a lipophilic platinum-based anticancer drug) from the Lipiodol/PCL beads in 11 days. We also found that the degradation speed could be controlled from 18.2% to 63.5% of the weight loss in 11 days by changing the molecular weight of PCL and the ratio of Lipiodol/PCL. The mean diameter of the bead could be well controlled by changing the flow-rate ratio of the microfluidic device. Regarding the radiopacity in vitro, the Lipiodol/PCL beads were clearly visualized through CT imaging, with a mean attenuation of over 5600 HU. Furthermore, it was found from the radiopacity experiments in vivo, that the embolization by the Lipiodol/PCL beads in the rabbit vessel was clearly recognized through CT images, indicating high potential of the newly synthesized biodegradable beads to improve the current TACE procedures by providing refined locational information on drug and embolic particles.

通过微流控装置，使用Lipiodol和聚己内酯（PCL）（Lipiodol / PCL微珠）制造了用于经动脉化学栓塞（TACE）的新的不透射线/可生物降解的药物洗脱微珠（DEB）。TACE是不可切除肝细胞癌（HCC）应用最广泛的疗法。DEB是栓塞性微球，具有持续的和肿瘤选择性的药物输送特性，可喂食动脉。由于常规的DEB本身不透射线且不可生物降解，因此在DEB-TACE程序后难以通过CT图像监测磁珠的定位和衰减，并且非目标栓塞后的并发症可能变得更加严重。在这项工作中，我们发现我们的新型可生物降解的Lipiodol / PCL在浸入11天后体重减轻了63.5％，同时释放了0。在11天之内从Lipiodol / PCL珠粒中获得94μgmiriplatin（一种亲脂性铂基抗癌药）。我们还发现，通过改变PCL的分子量和Lipiodol / PCL的比例，可以在11天内将降解速度控制在重量减轻的18.2％至63.5％之间。珠的平均直径可以通过改变微流体装置的流量比来很好地控制。关于体外射线不透性，可通过CT成像清楚地观察Lipiodol / PCL珠，平均衰减超过5600 HU。此外，从体内射线不透性实验中发现，通过CT图像可以清楚地识别出Lipiodol / PCL珠在兔血管中的栓塞，